Solventum (NYSE:SOLV) Price Target Raised to $71.00

Solventum (NYSE:SOLV) had its price target raised by The Goldman Sachs Group from $63.00 to $71.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a sell rating on the stock.

SOLV has been the topic of several other research reports. Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Piper Sandler increased their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.86.

Solventum Stock Performance

NYSE SOLV opened at $77.79 on Monday. The stock has a market cap of $13.44 billion and a PE ratio of 28.29. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum has a twelve month low of $47.16 and a twelve month high of $85.92. The stock has a fifty day simple moving average of $73.25 and a 200-day simple moving average of $70.39.

Hedge Funds Weigh In On Solventum

Hedge funds and other institutional investors have recently bought and sold shares of the company. Modus Advisors LLC acquired a new position in shares of Solventum in the fourth quarter worth $25,000. Clarity Asset Management Inc. acquired a new position in shares of Solventum in the fourth quarter worth $25,000. Stonebridge Financial Group LLC acquired a new position in shares of Solventum in the fourth quarter worth $26,000. Raiffeisen Bank International AG acquired a new position in shares of Solventum in the fourth quarter worth $29,000. Finally, Crews Bank & Trust acquired a new position in shares of Solventum in the fourth quarter worth $32,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.